Multiple sclerosis (MS), a chronic inflammatory disease of the spinal cord and brain, is the most common disabling neurological disease in young adults. Chronic pain is a common debilitating condition associated with MS. Pain symptoms that arise from damage to the nervous system, such as facial pain, are highly prevalent and, unfortunately, still lack efficient therapeutic agents. Most current medications for chronic pain are delivered systemically, are only partially effective, and are associated with frequent severe side effects.
This project proposes a preclinical investigation in a mouse model of MS of a novel approach for targeted delivery of a pain-relieving drug to reduce facial pain symptoms. This will be carried out using selective targeting of sensory neurons related to the face with gold nanoparticles coupled to a neuronal tracer and an approved drug for pain modulation to achieve a specific and controlled delivery of the nanomaterial to the brain.
The research outcomes will significantly advance the development of new selective nanomedicine that could overcome the limitations of current analgesic drug delivery in chronic pain associated with MS.
How to Apply
Express your interest in this project by emailing Associate Professor Gila Moalem-Taylor. Include a copy of your CV and your academic transcript(s).
School / Research Area
Biomedical Sciences
- Overview
- News
- Our team
- References